pembrolizumab + dabrafenib + trametinib

Pembrolizumab + dabrafenib + trametinib is a **combination regimen** used primarily in the treatment of BRAF V600-mutant advanced or metastatic melanoma. **Pembrolizumab** is a monoclonal antibody that inhibits the programmed death 1 (**PD-1**) checkpoint receptor, enhancing anti-tumor immune responses. **Dabrafenib** is a small molecule inhibitor targeting mutant **BRAF** kinase, specifically the V600E/K mutations that drive tumor proliferation. **Trametinib** is a small molecule inhibitor of **MEK1/2**, downstream effectors in the MAPK pathway. This triple therapy aims to combine targeted inhibition of the MAPK pathway through BRAF and MEK blockade with immunomodulation via PD-1 inhibition, resulting in enhanced anti-tumor efficacy compared to conventional doublet therapies. The regimen is in clinical development and use for advanced BRAF V600-mutant melanoma and is also being explored for other BRAF V600E-mutated malignancies[1][2][4][5][6].

Brand names

Keytruda + Tafinlar + Mekinist

Other names

Triple therapy (pembrolizumab, dabrafenib, trametinib)Pembrolizumab in Combination With Dabrafenib and Trametinib